BNCT treatments for cancer patients have started as part of a clinical trial
HUS has introduced the first in-hospital boron neutron capture therapy accelerator in Western countries. Boron neutron capture therapy, BNCT for short, is a radiation therapy method that can destroy cancer cells while sparing the surrounding tissue.
The first cancer patients received treatment with BNCT at Comprehensive Cancer Center in May as part of a study.
The launch of the treatments at HUS Comprehensive Cancer Center was made possible through a multi-year collaborative effort with the North American company Neutron Therapeutics. The Comprehensive Cancer Center was chosen as a partner because of the high quality of scientific BNCT research carried out at the center since 1992.
“The first BNCT center in Western countries presents a unique opportunity to develop this promising treatment method in close collaboration with Finnish and international research groups and offer cancer patients the chance to participate in various clinical trials,” says Johanna Mattson, Director of HUS Comprehensive Cancer Center.
Neutron capture therapy is targeted radiotherapy that spares the surrounding tissue
Boron neutron capture therapy, BNCT for short, is a type of targeted radiotherapy based on the decay reaction that occurs in boron atom nuclei delivered to the cancerous tumor when it is irradiated with neutrons.
Before the neutron irradiation, the patient is administered a boron delivery agent intravenously. The delivery agent accumulates in the cancer cells and delivers the boron inside the cells.
When the tumor area is irradiated with neutrons, it results in a very high local dose of radiation therapy in the cancer cells that contain boron.
“Short-range radiation effectively destroys the cancer cells while sparing the surrounding tissue. This requires fewer treatments than traditional radiation therapy, only one or two,” says Chief Medical Physicist Mikko Tenhunen from HUS Comprehensive Cancer Center.
The efficacy and safety of BNCT is being investigated in a clinical trial
A study was started at the Comprehensive Cancer Center to treat ten patients who have recurrent cancer in the head and neck area. The study assesses the safety and efficacy of BNCT.
“The goal is to extend the research program to other cancers in the future. Developing BNCT as a treatment also involves combining it with different cancer drugs and researching potential new boron delivery agents,” says Anu Anttonen, chief physician responsible for radiation therapy at HUS Comprehensive Cancer Center.
The media is welcome to visit the BNCT center on May 16 between noon and 1 p.m. Director Johanna Mattson and Chief Medical Physicist Mikko Tenhonen from HUS Comprehensive Cancer Center will be there for interviews. Please register by email viestinta@hus.fi or by telephone 050 427 2875.
Images
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Alla patienter som ska genomgå stötvågsbehandling av urinstenar behöver inte få antibiotika före behandlingen21.10.2025 07:47:57 EEST | Pressmeddelande
I en internationell prövning ledd av HUS undersöktes fördelarna, nackdelarna och behovet av antibiotika före stötvågsbehandling av urinstenar för att förebygga infektioner.
Kaikki potilaat eivät tarvitse antibioottia ennen virtsatiekivien murskaustoimenpidettä21.10.2025 07:47:57 EEST | Tiedote
HUSista johdetussa kansainvälisessä tutkimuksessa tarkasteltiin antibiootin hyötyjä, haittoja ja tarpeellisuutta ennen virtsakivien murskausta infektioiden ehkäisemiseksi.
Not all patients need antibiotics before shockwave lithotripsy for urolithiasis21.10.2025 07:47:57 EEST | Press release
An international study led by a HUS investigator examined the benefits, adverse effects, and necessity of antibiotics before shockwave lithotripsy in the prevention of infections.
God kognitiv funktionsförmåga kan främja återhämtning från en hjärnskada20.10.2025 08:27:58 EEST | Pressmeddelande
HUS studie inom neurokirurgi visar att en bra kognitiv kapacitet före en hjärnskada kan förbättra möjligheterna för återhämtning. En sämre kognitiv kapacitet kan däremot öka risken för en hjärnskada.
Hyvä kognitiivinen toimintakyky voi edistää aivovammasta toipumista20.10.2025 08:27:58 EEST | Tiedote
HUSin neurokirurgian tutkimus osoittaa, että hyvä kognitiivinen kapasiteetti ennen aivovammaa voi parantaa toipumismahdollisuuksia. Heikompi kognitiivinen kapasiteetti saattaa puolestaan lisätä riskiä saada aivovamma.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom